SCHEMBL384113

SCHEMBL384113

NC(=O)c1cnc(Cl)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 5/20 0.61
SIRT6 Q8N6T7 1/20 0.48
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
KMT2A Q03164 2/20 0.41
JAK2 O60674 2/20 0.38
JAK1 P23458 2/20 0.38
TYK2 P29597 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799541 1.00 NNMT (0.61) NNMTSIRT6CA12CA1CA2
Methoxymethane SCHEMBL27172554 0.93 NNMT (0.58) NNMTSIRT6CA12CA1CA2
SCHEMBL29577063 0.83 NNMT (0.42) NNMTSIRT6KMT2A
SCHEMBL16333365 0.83 NNMT (0.42) NNMTSIRT6KMT2A
SCHEMBL28662886 0.83 NNMT (0.42) NNMTSIRT6KMT2ALMNA
SCHEMBL17362420 0.82 SIRT6 (0.47) NNMTSIRT6MKNK1MKNK2LMNA
SCHEMBL625580 0.81 SMN1; SMN2 (0.47) NNMTSIRT6CA12CA1CA2
SCHEMBL29446081 0.81 SMN1; SMN2 (0.47) NNMTSIRT6CA12CA1CA2
SCHEMBL5878762 0.80 NNMT (0.62) NNMTCA12CA1CA2CA3
SCHEMBL22291660 0.80 NNMT (0.59) NNMTSIRT6MKNK1MKNK2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743068-B1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS INC (US) 2026-04-29 EP disclosed
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof ACCRO BIOSCIENCE HK LTD (HK) 2026-01-01 US disclosed
US-20250270190-A1 KIT INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-08-28 US disclosed
EP-4551559-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF Accro Bioscience (HK) Limited (HK) 2025-05-14 EP disclosed
US-12240840-B2 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha BRISTOL-MYERS SQUIBB COMPANY (US) 2025-03-04 US disclosed
US-12195475-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2025-01-14 US disclosed
US-20250011335-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2025-01-09 US disclosed
US-20240425456-A1 DEGRADER ASKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-26 US disclosed
WO-2024253416-A1 PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-12-12 WO disclosed
US-20240391934-A1 SUBSTITUTED PYRIDINES AND PYRIDAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LTD (GB) 2024-11-28 US disclosed
WO-2009111676-A2 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC (US) 2009-09-11 WO disclosed
WO-2009111676-A2 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC (US) 2009-09-11 WO disclosed
EP-1866286-B1 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMA (DE) 2009-05-27 EP disclosed
EP-1866286-B1 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMA (DE) 2009-05-27 EP disclosed
US-7468382-B2 Pyridine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-23 US disclosed
US-7468382-B2 Pyridine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-23 US disclosed
US-7468382-B2 Pyridine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-23 US disclosed
EP-1866286-A1 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-12-19 EP disclosed
WO-2006105023-A1 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-10-05 WO disclosed
US-20060217417-A1 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011335-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS TYK2, PDXK, JAK1 NNMT 838/4885SIRT6 1301/4885CA12 4846/4885
US-20240425456-A1 DEGRADER JAK3, JAK1, JAK2 NNMT 3109/4885SIRT6 2808/4885CA12 4106/4885
US-20240391934-A1 SUBSTITUTED PYRIDINES AND PYRIDAZINES AS TYK2 INHIBITORS TYK2, PDXK, TPX2 NNMT 1494/4885SIRT6 1124/4885CA12 4778/4885
US-20250270190-A1 KIT INHIBITORS KIT, ABL1, APC NNMT 2419/4885SIRT6 3128/4885CA12 3166/4885
US-12195475-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, ERBB3, MAP3K6 NNMT 507/4885SIRT6 1919/4885CA12 3858/4885
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof JAK1, JAK2, TYK2 NNMT 2150/4885SIRT6 1490/4885CA12 3342/4885
US-20060217417-A1 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA PRKCQ, PRKCH, PRKCZ NNMT 1646/4885SIRT6 2353/4885CA12 4055/4885
US-12240840-B2 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha TYK2, IFNG, JAK3 NNMT 2555/4885SIRT6 944/4885CA12 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.